Mangalam Drugs And Organics Ltd. is underperforming relative to its peers in the pharmaceuticals sector, exhibiting negative returns on equity and asset metrics, low revenue growth, and a high PEG ratio indicating overvaluation compared to growth. This positions it as a sector laggard with significant room for improvement in profitability and financial health.

• • Mangalam Drugs shows negative ROE and ROA, indicating poor profitability.
• • High PEG ratio reveals overvaluation despite stagnant revenue and earnings growth.
• • Compared to peers, the company has the highest debt-equity ratio among low-performers.